Axsome Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of AXS-05 in Smoking Cessation
23 avr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, April 23, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Presents Scientific Rationale for the Development of AXS-05 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
12 mars 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, March 12, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
07 mars 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Interim analyses of STRIDE-1 and ADVANCE-1 trials of AXS-05 anticipated in 2018 Company to host conference call today at 8:00 AM Eastern NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- Axsome...
Axsome Therapeutics Announces Primary Endpoint Met in Phase 1 Trial of Next Generation Product Candidate AXS-09 Containing Chirally Pure Esbupropion and Dextromethorphan
26 févr. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Chirally pure and stable single enantiomers of bupropion achieved AXS-09 consists of esbupropion and dextromethorphan for CNS disorders Esbupropion is the chirally pure S-enantiomer of bupropion ...
Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders
20 févr. 2018 07h00 HE
|
Wave Life Sciences
Wave to receive at least $230 million, including $110 million in upfront cash, $60 million in equity investment and at least $60 million in research support Takeda to receive option to co-develop...
Q Therapeutics Announces Research Collaboration With REPROCELL
13 déc. 2017 07h00 HE
|
Q Therapeutics, Inc.
SALT LAKE CITY and YOKOHAMA, Japan, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury,...
Axsome Therapeutics Reports Third Quarter 2017 Financial Results
08 nov. 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Precision Medicine Market growing at 10.5% CAGR to hit $96 bn by 2024
26 oct. 2017 07h00 HE
|
Global Market Insights, Inc
Ocean View, Delaware, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Precision Medicine Market is expected to cross USD 96 billion by 2024; according to a new research report by Global Market Insights. Rising...
Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors
19 juin 2017 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, June 19, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Aegis Awarded Patent for Non-invasive Nasal Anti-Seizure Drug Formulations
10 mai 2017 08h30 HE
|
Aegis Therapeutics LLC
SAN DIEGO, CA--(Marketwired - May 10, 2017) - Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,642,913, the fourth patent providing non-invasive metered nasal spray...